BRPI0411095A - derivados de imidazol - Google Patents

derivados de imidazol

Info

Publication number
BRPI0411095A
BRPI0411095A BRPI0411095-1A BRPI0411095A BRPI0411095A BR PI0411095 A BRPI0411095 A BR PI0411095A BR PI0411095 A BRPI0411095 A BR PI0411095A BR PI0411095 A BRPI0411095 A BR PI0411095A
Authority
BR
Brazil
Prior art keywords
imidazole derivatives
manufacture
derivatives
mglur5 receptor
immedazole
Prior art date
Application number
BRPI0411095-1A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Phillip Porter
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0411095A publication Critical patent/BRPI0411095A/pt
Publication of BRPI0411095B1 publication Critical patent/BRPI0411095B1/pt
Publication of BRPI0411095B8 publication Critical patent/BRPI0411095B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE IMIDAZOL". A presente invenção diz respeito aos derivados de imidazol que são antagonistas do receptor de mGluR5 e que são representados pela fórmula geral (I): em que R¬ 1¬, R¬ 2¬, R¬ 3¬ e R¬ 4¬ são como definidos no relatório descritivo, a um processo para a sua fabricação, assim como aos seus sais farmaceuticamente aceitáveis para a fabricação de um medicamento para o tratamento ou prevenção dos distúrbios mediados pelo receptor de mGluR5, tais como os distúrbios neurológicos agudos e/ou crónicos.
BRPI0411095A 2003-06-05 2004-06-01 derivados de imidazol, seus usos e seus processos de preparação, e medicamentos BRPI0411095B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05
EP03012200.6 2003-06-05
PCT/EP2004/005881 WO2004108701A1 (en) 2003-06-05 2004-06-01 Imidazole derivatives as glutmate receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0411095A true BRPI0411095A (pt) 2006-07-18
BRPI0411095B1 BRPI0411095B1 (pt) 2018-04-03
BRPI0411095B8 BRPI0411095B8 (pt) 2021-05-25

Family

ID=33483899

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411095A BRPI0411095B8 (pt) 2003-06-05 2004-06-01 derivados de imidazol, seus usos e seus processos de preparação, e medicamentos

Country Status (39)

Country Link
US (3) US7332510B2 (pt)
EP (1) EP1636206B1 (pt)
JP (1) JP4401384B2 (pt)
KR (1) KR100778948B1 (pt)
CN (1) CN100408572C (pt)
AR (1) AR044478A1 (pt)
AT (1) ATE377008T1 (pt)
AU (1) AU2004245208B2 (pt)
BR (1) BRPI0411095B8 (pt)
CA (1) CA2527315C (pt)
CL (1) CL2004001347A1 (pt)
CR (1) CR8094A (pt)
CY (1) CY1107856T1 (pt)
DE (1) DE602004009796T2 (pt)
DK (1) DK1636206T3 (pt)
EA (1) EA010577B1 (pt)
EC (1) ECSP056202A (pt)
ES (1) ES2294504T3 (pt)
GT (1) GT200400117A (pt)
HK (1) HK1093070A1 (pt)
HN (1) HN2004000208A (pt)
HR (1) HRP20070529T3 (pt)
IL (1) IL171930A (pt)
MA (1) MA27881A1 (pt)
MX (1) MXPA05013149A (pt)
MY (2) MY137272A (pt)
NO (1) NO332143B1 (pt)
NZ (1) NZ543637A (pt)
PA (1) PA8604101A1 (pt)
PE (1) PE20050162A1 (pt)
PL (1) PL1636206T3 (pt)
PT (1) PT1636206E (pt)
RS (1) RS53183B (pt)
SI (1) SI1636206T1 (pt)
TN (2) TNSN05309A1 (pt)
TW (1) TWI338007B (pt)
UA (1) UA80888C2 (pt)
WO (1) WO2004108701A1 (pt)
ZA (2) ZA200509807B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
BRPI0511678A (pt) 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
AU2013333988B2 (en) * 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
PE20150733A1 (es) * 2012-10-18 2015-05-17 Hoffmann La Roche Derivados de etinilo como moduladores de la actividad del receptor mglur5
EP3436009B1 (en) * 2016-03-30 2024-03-06 Sinntaxis AB Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages.
CN116056701A (zh) * 2020-06-05 2023-05-02 诺埃玛制药公司 治疗结节硬化复合症的方法
MX2023001288A (es) * 2020-07-30 2023-04-28 Noema Pharma Ag Metodos de tratamiento de la neuralgia del trigemino.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079312A3 (de) 1981-11-11 1984-04-25 Ciba-Geigy Ag Heterocyclische Acetylenverbindungen
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
KR100515549B1 (ko) * 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체
WO2003053922A2 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2004038374A2 (en) * 2002-10-24 2004-05-06 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
DE602004009796D1 (de) 2007-12-13
UA80888C2 (en) 2007-11-12
JP4401384B2 (ja) 2010-01-20
EP1636206B1 (en) 2007-10-31
PT1636206E (pt) 2008-01-28
MXPA05013149A (es) 2006-03-17
KR100778948B1 (ko) 2007-11-28
ECSP056202A (es) 2006-04-19
CN100408572C (zh) 2008-08-06
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
PE20050162A1 (es) 2005-03-22
US20040248888A1 (en) 2004-12-09
PA8604101A1 (es) 2004-12-16
CA2527315A1 (en) 2004-12-16
TNSN05309A1 (fr) 2007-07-10
JP2006526588A (ja) 2006-11-24
BRPI0411095B8 (pt) 2021-05-25
IL171930A (en) 2010-12-30
NZ543637A (en) 2008-04-30
US20080119489A1 (en) 2008-05-22
HRP20070529T3 (en) 2008-05-31
HN2004000208A (es) 2009-02-03
BRPI0411095B1 (pt) 2018-04-03
ES2294504T3 (es) 2008-04-01
EA010577B1 (ru) 2008-10-30
RS20050892A (en) 2007-12-31
AU2004245208A1 (en) 2004-12-16
RS53183B (en) 2014-06-30
GT200400117A (es) 2005-02-07
AR044478A1 (es) 2005-09-14
ATE377008T1 (de) 2007-11-15
WO2004108701A1 (en) 2004-12-16
MY143353A (en) 2011-04-29
MY137272A (en) 2009-01-30
NO332143B1 (no) 2012-07-02
TW200509920A (en) 2005-03-16
CY1107856T1 (el) 2013-06-19
US7332510B2 (en) 2008-02-19
ZA200609681B (en) 2008-06-25
HK1093070A1 (en) 2007-02-23
MA27881A1 (fr) 2006-05-02
US7973165B2 (en) 2011-07-05
IL171930A0 (en) 2006-04-10
CR8094A (es) 2006-05-30
CN1802367A (zh) 2006-07-12
TNSN06391A1 (fr) 2008-02-22
CA2527315C (en) 2010-08-10
PL1636206T3 (pl) 2008-04-30
EP1636206A1 (en) 2006-03-22
CL2004001347A1 (es) 2005-05-06
NO20055465L (no) 2005-11-18
AU2004245208B2 (en) 2007-04-26
ZA200509807B (en) 2006-12-27
EA200501887A1 (ru) 2006-10-27
DE602004009796T2 (de) 2008-08-28
SI1636206T1 (sl) 2008-02-29
DK1636206T3 (da) 2008-02-11
TWI338007B (en) 2011-03-01
US8481548B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
BRPI0411095A (pt) derivados de imidazol
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0208373A (pt) Inibidores da tirosina cinase
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BR0213233A (pt) Alcinos inibidores de metaloproteinase de matriz
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BR0314059A (pt) Compostos heterocìclicos
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0512986A (pt) novos derivados de hidantoìna
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
RS20050363A (en) Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
BR0317455A (pt) Derivados de pirrol-pirazol substituìdos como inibidores de quinase
BR0009044A (pt) Composto, composição farmacêutica, método para tratar uma doença em um animal, uso de um composto, e, processo para fabricar um composto
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
BR0112093A (pt) Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF